Studies were conducted to determine the mechanism of blood pressure-and cholesterol-lowering effects of funoran on rats fed with a saline solution and cholesterol diet. Clofibrate (COIB) was used as a reference hypolipidemic drug. Funoran caused significant reduction of systolic blood pressure (SBP). Funoran and CPIB significantly reduced serum total cholesterol (TC), free cholesterol (FC), triglyceride (TG), LDL-cholesterol (LDL), and atherogenic index (AI) levels in these rats. The increase of sodium, water excretion and sodium-potassium ratio in urine in the funoran group was more significant in the experimental rats thannnnin the control group. Moreover, the ratio of Na and K in serum decreased with the funoran diet. The CPIB diet enhanced cholesterol level in the liver while the funoran diet suppressed the level, but in feces the former diet did not change the cholesterol level while the latter diet increased it. These results suggest that the enhanced ability to excrete sodium in urine by the funoran diet is an important factor for reducing blood pressure and that the antihyperlipidemic effect of funoran was not caused by the mobilization of peripheral cholesterol on the liver, but by the enhanced excretion of cholesterol into feces.
The animals were not fed for 8 h prior to this sodium load, however they were allowed to drink distilled water. Three hours after the saline loading, urine was collected using small isolation cages. Urinary volume, sodium, and potassium excretions were measured. Electrolyte concentrations in urine were analyzed by the electrode method using an automated electrolyte analyzer, EA 06 T/R (A& T Co., Ltd., Tokyo).
Measurement of Serum Electrolyte
The rats were kept at the above conditions. At the end of the experiment, the rats were starved for 12-14h prior to collection of blood from the heart. Electrolyte concentrations in serum were analyzed by the electrode method using an automated electrolyte analyzer, EA 06 T/R (A&T Co., Ltd., Tokyo).
Determination of Serum Lipid Level
At the end of the experiment, the rats were starved for 12-14 h prior to collection of blood from the heart. Total cholesterol (TC), free cholesterol (FC), triglyceride (TG), and HDL-cholesterol (HDL) in serum were assayed by an enzymatic method,14,15) using a cholesterol E-Test Wako (Wako Pure Chemical Industries Ltd.) and a Spectrophotometer, ATAGO AT-60. LDL-cholesterol (LDL) was estimated using the following equation: LDL=TC-HDL.
Atherogenic Index (AI) was referred to TC-HDL/HDL. 
Results
Change of Body Weight Changes in body weight are shown in Fig. 1 . The body weights of the funoran and CPIB groups were slightly higher than the control group after 16 days of feeding. During the experiment, the physical appearance of the rats was good.
Antihypertensive Effect of Funoran
The results of the antihypertensive effects of funoran are illustrated in Fig. 2 . The animals fed with the algal polysaccharide diet were examined for changes in their SBP during 20 days of feeding. The SBP of the group fed with the funoran was markedly lower than that of the control group. The SBP of the funoran group was significantly (p <0.05) lower than that of the control group at 8 days of feeding. The SBP of the funoran group significantly (p<0.001) decreased to 86.0% compared with the control group on the last day of feeding.
Influence of Funoran on Urine Electrolytes
The results of the funoran on urine electrolytes are summarized in Table 1 . The urinary excretion rate for 3 h urine samples was 139.0% higher in the funoran group than in the control group. Excretion of sodium and chlorine was enhanced, and the Na+/K+ ratio was also 257.0% higher in the urine of the funoran group than in the control group. On the contrary, the excretion of potassium was significantly lower (62.0%) in the funoran than in the control groups. 
Influence of Funoran on Serum Electrolytes
The results of the funoran on serum electrolytes are shown in Table 2 . After 20 days, the potassium level of the funoran group in serum increased to 114.0% compared with the control group. The ratio of sodium and potassium levels in the funoran group was significantly lower (87.0%) than in the control group. However, the amounts of sodium and chlorine in serum were almost the same in the funoran and the control groups.
Hypocholesterolemic Effect of Funoran and CPIB
The effects of the diet containing funoran on the serum lipid level of rats with hypercholesterolmia are shown in Table 3 . The funoran and CPIB groups showed a reduction in the Atherogenic Index of serum (61.0 and 70.0%, re spectively) compared with the control group.
TC concentrations of the funoran group significantly decreased to 69.0% of the control group. The CPIB group also showed a similar result. The funoran and CPIB groups also showed remarkably lower levels of FC, TG, and LDL (52.0-66.0% of the control).
In contrast, the HDL concentration of the funoran group remained almost unchanged, while that of the CPIB group reduced remarkably (79.0%) compared with the control group.
Effect of Funoran or CPIB on Liver Cholesterol Level
The effects of the diet containing funoran on the liver cholesterol level of rats with hypercholesterolmia are shown in Table 4 . The body weight of both the funoran and CPIB groups increased significantly during 20 days of feeding. In contrast, the total liver weight of the CPIB group markedly increased to as much as 135.0% of the control group, while no increase was found in the funoran group. In addition, the total liver cholesterol level of the CPIB group was enhanced significantly (127.0%) compared to the control group, although no difference was found in the liver cholesterol level between the funoran and control groups.
Effect of Funoran and CPIB on Fecal Cholesterol Level
The effects of the diet containing funoran on the fecal cholesterol level of rats with hypercholesterolmia are shown in Table 5 . The food intake of the funoran and CPIB groups increased to 116.0 and 123.0% of the control group. The fecal excretion of cholesterol increased significantly in the funoran group to 142.0% higher than that of the control group. However, the CPIB group showed no such trend despite an increase of 134.0% in the fecal amount. Ren et al . of blood pressure. Finally , a direct effect of potassium concentration on the resistance vessels is another possi ble mechanism. There is convincing evidence that an in crease in plasma potassium concentration exerts a direct vasodilator effect on vessels.30,31) Therefore , the urine level of K+ excretion and the increase in its serum level may be important factors in the antihypertensive effect of the funoran.
In the present study, the funoran and CPIB depressed TC, FC, TG, LDL, and Al levels in the sodium and cholesterol loaded rats. The funoran group increased HDL levels in the serum, whereas the CPIB significantly lowered HDL levels. Particularly low levels of FC and TG of 52.0 and 53.0% of control levels were observed in the funoran group.
The rats fed with the cholesterol diet were examined for its effects on the metabolism in liver and feces . In the test groups, the funoran markedly increased fecal excretion of cholesterol, but the liver cholesterol level in cholesterol-fed rats did not change. However , the CPIB group showed the opposite effect. CPIB is an extensively used hypolipidemic drug32-34) that has been particularly effective in lowering triglycerides35) but it has no effect on cholesterol absorption and excretion.36) Thus, the antihyperlipidemic mechanism of funoran is not the same as that of CPIB . The present data suggest that the mechanism of the hypolipidemic effect of funoran is due to the prevention of dietary cholesterol absorption and enhancement of cholesterol excretion in feces.
Hypertension is a major risk factor for arteriosclerosis37-39) and the beneficial effects of lowering blood pressure on morbidity and mortality is well documente d. [40] [41] [42] [43] Previous studies also have emphasized the positive relationship of TC, LDL, and TG with the risk of coronary heart disease (CHD). [44] [45] [46] [47] The higher the concentration of any one of these blood lipids, the greater the risk of CHD. On the other hand, HDL appears to have an inverse relation on the risk of CHD.42,48-52) Low HDL con centrations lead to an increased risk of CHD. Moreover , many hypertensive therapies53,54) adversely interfere with the lipid profile by accompanying lowered HDL, raising TG and TC levels. Some investigators55) believe that these effects may reflect why the decline in CHD incidence has been so small in most hypertension intervention trials. Our data demonstrates that funoran has an antihypertensive effect and also inhibits the reduction of serum HDL levels and decreased TC, TG, LDL, and Al levels after 20 days of ingesting a high salt and cholesterol diet. Our studies therefore suggest the usefulness of funoran as an antihypertensive and antihyperlipidemic medicine . 
